echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA: Compared with blood glucose meters, can continuous blood glucose monitoring improve the level of glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes?

    JAMA: Compared with blood glucose meters, can continuous blood glucose monitoring improve the level of glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes?

    • Last Update: 2021-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A study based on data from the National Health and Nutrition Survey (NHANES) from 2005 to 2012 estimated that about 30% of American type 2 diabetes patients received insulin therapy, and about two-thirds of them used basal insulin instead of basal insulin.
    Pre-meal insulin, however, only 62% of insulin patients have hemoglobin A1c (HbA1c) levels below 8.
    0%, and 31% have levels below 7.
    0%.
    A recent evaluation of NHANES data shows that between 2005 and 2016, there was no improvement in the blood glucose results of diabetes in the United States.

    A study based on data from the National Health and Nutrition Survey (NHANES) from 2005 to 2012 estimated that about 30% of American type 2 diabetes patients received insulin therapy, and about two-thirds of them used basal insulin instead of basal insulin.
    Pre-meal insulin, however, only 62% of insulin patients have hemoglobin A1c (HbA1c) levels below 8.
    0%, and 31% have levels below 7.
    0%.
    A recent evaluation of NHANES data shows that between 2005 and 2016, there was no improvement in the blood glucose results of diabetes in the United States.
    A recent evaluation of NHANES data shows that between 2005 and 2016, there was no improvement in the blood glucose results of diabetes in the United States.
    A recent evaluation of NHANES data shows that between 2005 and 2016, there was no improvement in the blood glucose results of diabetes in the United States.

    Pixabay.
    com

    Pixabay.
    com
    Pixabay.
    com

    Blood glucose monitoring is an important part of diabetes management.
    The results of blood glucose monitoring can help assess the degree of glucose metabolism disorders in diabetic patients, formulate a reasonable hypoglycemic plan, follow up changes in the condition, and guide the adjustment of treatment plans.
    Patient self-monitoring of blood glucose (SMBG) is the basic form of blood glucose monitoring, and glycosylated hemoglobin (HbA1c) is the gold standard that reflects the average level of long-term blood glucose control.

    Blood glucose monitoring is an important part of diabetes management.
    The results of blood glucose monitoring can help assess the degree of glucose metabolism disorders in diabetic patients, formulate a reasonable hypoglycemic plan, follow up changes in the condition, and guide the adjustment of treatment plans.
    Patient self-monitoring of blood glucose (SMBG) is the basic form of blood glucose monitoring, and glycosylated hemoglobin (HbA1c) is the gold standard that reflects the average level of long-term blood glucose control.
    Blood glucose monitoring is an important part of diabetes management.
    The results of blood glucose monitoring can help assess the degree of glucose metabolism disorders in diabetic patients, formulate a reasonable hypoglycemic plan, follow up changes in the condition, and guide the adjustment of treatment plans.
    Patient self-monitoring of blood glucose (SMBG) is the basic form of blood glucose monitoring, and glycosylated hemoglobin (HbA1c) is the gold standard that reflects the average level of long-term blood glucose control.
    Patient self-monitoring of blood glucose (SMBG) is the basic form of blood glucose monitoring, and glycosylated hemoglobin (HbA1c) is the gold standard that reflects the average level of long-term blood glucose control.
    Patient self-monitoring of blood glucose (SMBG) is the basic form of blood glucose monitoring, and glycosylated hemoglobin (HbA1c) is the gold standard that reflects the average level of long-term blood glucose control.

    Real-time continuous blood glucose monitoring (CGM) is mainly applied to patients with type 1 diabetes who need insulin injections.
    By providing blood glucose measurement, low and high blood glucose alarms and blood glucose trend information every 5 minutes, compared with the intermittent self-monitoring of BGM, it has May provide better information for diabetes management decisions.
    So, for adults with type 2 diabetes who use basal insulin therapy instead of dietary insulin in primary care practice, can continuous blood glucose monitoring improve the level of glycosylated hemoglobin (HbA1c) compared with blood glucose meter monitoring?

    Real-time continuous blood glucose monitoring (CGM) is mainly applied to patients with type 1 diabetes who need insulin injections.
    By providing blood glucose measurement, low and high blood glucose alarms and blood glucose trend information every 5 minutes, compared with the intermittent self-monitoring of BGM, it has May provide better information for diabetes management decisions.
    So, for adults with type 2 diabetes who use basal insulin therapy instead of dietary insulin in primary care practice, can continuous blood glucose monitoring improve the level of glycosylated hemoglobin (HbA1c) compared with blood glucose meter monitoring?
    Real-time continuous blood glucose monitoring (CGM) is mainly applied to patients with type 1 diabetes who need insulin injections.
    By providing blood glucose measurement, low and high blood glucose alarms and blood glucose trend information every 5 minutes, compared with the intermittent self-monitoring of BGM, it has May provide better information for diabetes management decisions.
    So, for adults with type 2 diabetes who use basal insulin therapy instead of dietary insulin in primary care practice, can continuous blood glucose monitoring improve the level of glycosylated hemoglobin (HbA1c) compared with blood glucose meter monitoring?
    So, for adults with type 2 diabetes who use basal insulin therapy instead of dietary insulin in primary care practice, can continuous blood glucose monitoring improve the level of glycosylated hemoglobin (HbA1c) compared with blood glucose meter monitoring? So, for adults with type 2 diabetes who use basal insulin therapy instead of dietary insulin in primary care practice, can continuous blood glucose monitoring improve the level of glycosylated hemoglobin (HbA1c) compared with blood glucose meter monitoring?

    This randomized clinical trial was conducted in 15 centers in the United States (registered from July 30, 2018 to October 30, 2019; follow-up completed on July 7, 2020), including adults with type 2 diabetes who received diabetes care, injected daily 1-2 times long-term or medium-term basal insulin, without dietary insulin, or without non-insulin hypoglycemic drugs.
    Random 2:1 CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59).
    The main result is the level of glycosylated hemoglobin (HbA1c) at 8 months.
    The main secondary results are the time the CGM measures the target blood glucose range of 70-180 mg/dL, the time the blood glucose level is greater than 250 mg/dL, and the average blood glucose level at 8 months.

    This randomized clinical trial was conducted in 15 centers in the United States (registered from July 30, 2018 to October 30, 2019; follow-up completed on July 7, 2020), including adults with type 2 diabetes who received diabetes care, injected daily 1-2 times long-term or medium-term basal insulin, without dietary insulin, or without non-insulin hypoglycemic drugs.
    Random 2:1 CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59).
    The main result is the level of glycosylated hemoglobin (HbA1c) at 8 months.
    The main secondary results are the time the CGM measures the target blood glucose range of 70-180 mg/dL, the time the blood glucose level is greater than 250 mg/dL, and the average blood glucose level at 8 months.
    This randomized clinical trial was conducted in 15 centers in the United States (registered from July 30, 2018 to October 30, 2019; follow-up completed on July 7, 2020), including adults with type 2 diabetes who received diabetes care, injected daily 1-2 times long-term or medium-term basal insulin, without dietary insulin, or without non-insulin hypoglycemic drugs.
    Random 2:1 CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59).
    The main result is the level of glycosylated hemoglobin (HbA1c) at 8 months.
    The main secondary results are the time the CGM measures the target blood glucose range of 70-180 mg/dL, the time the blood glucose level is greater than 250 mg/dL, and the average blood glucose level at 8 months.
    This randomized clinical trial was conducted in 15 centers in the United States (registered from July 30, 2018 to October 30, 2019;follow-up completed on July 7, 2020), including adults with type 2 diabetes who received diabetes care, injected daily 1-2 times long-term or medium-term basal insulin, without dietary insulin, or without non-insulin hypoglycemic drugs.
    Random 2:1 CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59).
    The main result is the level of glycosylated hemoglobin (HbA1c) at 8 months.
    The main secondary results are the time the CGM measures the target blood glucose range of 70-180 mg/dL, the time the blood glucose level is greater than 250 mg/dL, and the average blood glucose level at 8 months.
    The main result is the level of glycosylated hemoglobin (HbA1c) at 8 months.
    The main secondary results are the time the CGM measures the target blood glucose range of 70-180 mg/dL, the time the blood glucose level is greater than 250 mg/dL, and the average blood glucose level at 8 months.

    The results of the study showed that out of 175 random participants, 165 (94%) completed the trial.
    The average HbA1c level in the CGM group decreased from 9.
    1% at baseline to 8.
    0% at 8 months, and the average HbA1c level in the BGM group decreased from 9.
    0% to 8.
    4%.
    In the CGM group, compared with the BGM group, the average percentage of CGM measurement time within the target blood glucose range of 70-180 mg/dL was 59% vs.
    43%, and the average percentage of CGM greater than 250 mg/dL was 11% vs.
    27%.
    The average percentage of the average blood glucose level is 179 mg/dL vs.
    206 mg/dL.
    There were 1 case (1%) and 1 case (2%) in the CGM group and 1 case (2%) in the CGM group and BGM group, respectively.

    The results of the study showed that out of 175 random participants, 165 (94%) completed the trial.
    The average HbA1c level in the CGM group decreased from 9.
    1% at baseline to 8.
    0% at 8 months, and the average HbA1c level in the BGM group decreased from 9.
    0% to 8.
    4%.
    In the CGM group, compared with the BGM group, the average percentage of CGM measurement time within the target blood glucose range of 70-180 mg/dL was 59% vs.
    43%, and the average percentage of CGM greater than 250 mg/dL was 11% vs.
    27%.
    The average percentage of the average blood glucose level is 179 mg/dL vs.
    206 mg/dL.
    There were 1 case (1%) and 1 case (2%) in the CGM group and 1 case (2%) in the CGM group and BGM group, respectively.
    The results of the study showed that out of 175 random participants, 165 (94%) completed the trial.
    The average HbA1c level in the CGM group decreased from 9.
    1% at baseline to 8.
    0% at 8 months, and the average HbA1c level in the BGM group decreased from 9.
    0% to 8.
    4%.
    In the CGM group, compared with the BGM group, the average percentage of CGM measurement time within the target blood glucose range of 70-180 mg/dL was 59% vs.
    43%, and the average percentage of CGM greater than 250 mg/dL was 11% vs.
    27%.
    The average percentage of the average blood glucose level is 179 mg/dL vs.
    206 mg/dL.
    There were 1 case (1%) and 1 case (2%) in the CGM group and 1 case (2%) in the CGM group and BGM group, respectively.
    The results of the study showed that out of 175 random participants, 165 (94%) completed the trial.
    The average HbA1c level in the CGM group decreased from 9.
    1% at baseline to 8.
    0% at 8 months, and the average HbA1c level in the BGM group decreased from 9.
    0% to 8.
    4%.
    In the CGM group, compared with the BGM group, the average percentage of CGM measurement time within the target blood glucose range of 70-180 mg/dL was 59% vs.
    43%, and the average percentage of CGM greater than 250 mg/dL was 11% vs.
    27%.
    The average percentage of the average blood glucose level is 179 mg/dL vs.
    206 mg/dL.
    There were 1 case (1%) and 1 case (2%) in the CGM group and 1 case (2%) in the CGM group and BGM group, respectively.
    The results of the study showed that out of 175 random participants, 165 (94%) completed the trial.
    The average HbA1c level in the CGM group decreased from 9.
    1% at baseline to 8.
    0% at 8 months, and the average HbA1c level in the BGM group decreased from 9.
    0% to 8.
    4%.
    In the CGM group, compared with the BGM group, the average percentage of CGM measurement time within the target blood glucose range of 70-180 mg/dL was 59% vs.
    43%, and the average percentage of CGM greater than 250 mg/dL was 11% vs.
    27%.
    The average percentage of the average blood glucose level is 179 mg/dL vs.
    206 mg/dL.
    There were 1 case (1%) and 1 case (2%) in the CGM group and 1 case (2%) in the CGM group and BGM group, respectively.
    The average HbA1c level in the CGM group decreased from 9.
    1% at baseline to 8.
    0% at 8 months, and the average HbA1c level in the BGM group decreased from 9.
    0% to 8.
    4%.
    In the CGM group, compared with the BGM group, the average percentage of CGM measurement time within the target blood glucose range of 70-180 mg/dL was 59% vs.
    43%, and the average percentage of CGM greater than 250 mg/dL was 11% vs.
    27%.
    The average percentage of the average blood glucose level is 179 mg/dL vs.
    206 mg/dL.
    There were 1 case (1%) and 1 case (2%) in the CGM group and 1 case (2%) in the CGM group and BGM group, respectively.
    The average HbA1c level in the CGM group decreased from 9.
    1% at baseline to 8.
    0% at 8 months, and the average HbA1c level in the BGM group decreased from 9.
    0% to 8.
    4%.
    In the CGM group, compared with the BGM group, the average percentage of CGM measurement time within the target blood glucose range of 70-180 mg/dL was 59% vs.
    43%, and the average percentage of CGM greater than 250 mg/dL was 11% vs.
    27%.
    The average percentage of the average blood glucose level is 179 mg/dL vs.
    206 mg/dL.
    There were 1 case (1%) and 1 case (2%) in the CGM group and 1 case (2%) in the CGM group and BGM group, respectively.

    Hemoglobin A1c (HbA1c): Value at 8 months

    Hemoglobin A1c (HbA1c): Value at 8 months Hemoglobin A1c (HbA1c): Value at 8 months Hemoglobin A1c (HbA1c): Value at 8 months

    In this randomized trial, patients with type 2 diabetes had poor blood glucose control (average glycosylated hemoglobin level of 9.
    1%), and the results confirmed that
    in patients with type 2 diabetes who were treated with basal insulin instead of dietary insulin, continuous blood glucose Compared with monitoring by blood glucose meter, HbA1c level was significantly reduced at 8 months.

    In this randomized trial, patients with type 2 diabetes had poor blood glucose control (average glycosylated hemoglobin level of 9.
    1%), and the results confirmed that
    in patients with type 2 diabetes who were treated with basal insulin instead of dietary insulin, continuous blood glucose Compared with monitoring by blood glucose meter, HbA1c level was significantly reduced at 8 months.
    In this randomized trial, patients with type 2 diabetes had poor blood glucose control (average glycosylated hemoglobin level of 9.
    1%), and the results confirmed that
    in patients with type 2 diabetes who were treated with basal insulin instead of dietary insulin, continuous blood glucose Compared with monitoring by blood glucose meter, HbA1c level was significantly reduced at 8 months.
    In patients with type 2 diabetes who were treated with basal insulin but not dietary insulin, continuous blood glucose monitoring compared with blood glucose meter monitoring showed a significant decrease in HbA1c levels at 8 months.
    In patients with type 2 diabetes who were treated with basal insulin instead of dietary insulin, continuous blood glucose monitoring compared with blood glucose meter monitoring showed a significant decrease in HbA1c levels at 8 months.

    References: Martens T, Beck RW, Bailey R, et al.
    Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
    A Randomized Clinical Trial .
     
    JAMA.
     Published online June 02, 2021.
    doi: 10.
    1001/jama.
    2021.
    7444

    References: Martens T, Beck RW, Bailey R, et al.
    Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
    A Randomized Clinical Trial .
     
    JAMA.
     Published online June 02, 2021.
    doi: 10.
    1001/jama.
    2021.
    7444
    References: Martens T, Beck RW, Bailey R, et al.
    Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
    A Randomized Clinical Trial .
     
    JAMA.
     Published online June 02 , 2021.
    doi:10.
    1001/jama.
    2021.
    7444
    .
    Martens T, Beck RW, R & lt Bailey, et Al Effect of the Continuous Glucose Monitoring ON Glycemic Control in Patients Treated With the Type 2 Diabetes With Basal Insulin
    A Randomized Clinical Trial .
     
    JAMA.
     Published Online June 02, 2021.
    DOI: 10.
    1001 / jama.
    2021.
    7444
    doi:10.
    1001/jama.
    2021.
    7444


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.